Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Inclusion Criteria:

• Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score 8.
• Methotrexate >7.5 mg/week for the last 3 months

Exclusion Criteria:

• Predominantly guttate, erythrodermic or pustular psoriasis
• Other skin conditions than psoriasis